InsidersTradesSigma
Follow the Charlotte's Web Holdings, Inc. stock price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Charlotte's Web Holdings, Inc. has logged 108 reports. Market capitalisation: €84.4m. The latest transaction was disclosed on 8 September 2026 (10 - Acquisition or disposition in the public market). Among the most active insiders: Morachnick William J.. The full history is accessible without an account.
108
Insider Decl.
n/a
Thresholds
€41,640
4 ops.
Buy Volume
€73,707
1 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Charlotte's Web Holdings, Inc. Strong Buy (bullish).
26Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,673 of 29,063 companies
15.6
score / 100
Value9
Quality22
FCF yld-17%
Earn yld-35%
EV/EBITDA·
ROE-97%
Gross mgn43%
Net mgn-60%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 8 September 2026
Declarations108 total
137,935 shares@ CA$0.2848Common SharesTSXSEDI:4773849
Canonical exit: 2 Dec 2026 (T+90)
85,000 sharesRights Restricted Share AwardsTSXSEDI:4747816
85,000 sharesCommon SharesTSXSEDI:4747814
Canonical exit: 4 Oct 2026 (T+90)
75,000 sharesRights Restricted Share AwardsTSXSEDI:4747783
75,000 sharesCommon SharesTSXSEDI:4747781
Canonical exit: 4 Oct 2026 (T+90)
75,000 sharesRights Restricted Share AwardsTSXSEDI:4747292
75,000 sharesCommon SharesTSXSEDI:4747288
Canonical exit: 4 Oct 2026 (T+90)
294,661 sharesRights Restricted Share AwardsTSXSEDI:4747212
222,911 sharesCommon SharesTSXSEDI:4747206
Canonical exit: 4 Oct 2026 (T+90)
71,750 shares@ US$0.310.025% mcap10.6% of flowCommon SharesSEC:0001750155-26-000107:1
75,000 shares0Common SharesSEC:0001750155-26-000106:0
75,000 shares0Common SharesSEC:0001750155-26-000104:0
85,000 shares0Common SharesSEC:0001750155-26-000105:0
294,661 shares0Common SharesSEC:0001750155-26-000107:0
91,313 shares@ CA$0.310.020% mcap100.0% of flowCommon SharesTSXSEDI:4743891
Canonical exit: 28 Sept 2026 (T+90)
375,000 sharesRights Restricted Share AwardsTSXSEDI:4743890
375,000 sharesCommon SharesTSXSEDI:4743884
Canonical exit: 28 Sept 2026 (T+90)
375,000 sharesCommon SharesTSXSEDI:4743689
Canonical exit: 28 Sept 2026 (T+90)
Convertible Debentures Due November 2029TSXSEDI:4727533
Rights Restricted Share AwardsTSXSEDI:4727532
Proportionate Voting SharesTSXSEDI:4727530
OptionsTSXSEDI:4727529
Common SharesTSXSEDI:4727527
75,000 sharesRights Restricted Share AwardsTSXSEDI:4726962
75,000 sharesRights Restricted Share AwardsTSXSEDI:4726960
25 of 108 declarations
关于 Charlotte's Web Holdings, Inc.
Charlotte’s Web Holdings, Inc. 是一家总部位于美国的专注于大麻提取物和植物性健康产品的公司。它是一家 SEC 报告发行人，通过 Form 4 文件披露内部人活动，其股票主要在美国小盘股/OTC 生态系统中受到关注，同时市场参考也可能出现在 NYSE/NASDAQ 筛选和数据源中。对于国际投资者而言，该公司应被视为消费健康和保健品牌，而非传统的制药开发商。Charlotte’s Web 总部位于美国科罗拉多州路易斯维尔，其大部分业务在美国开展 ([sec.gov](https://www.sec.gov/Archives/edgar/data/1750155/000175015526000029/cweb-20251231.htm?utm_source=openai)) 该公司围绕其 Charlotte’s Web 品牌和专有大麻遗传学建立，发展成为一个以大麻二酚 (CBD) 及相关植物成分为核心的平台。其品牌家族目前包括 Charlotte’s Web™、CBD Medic™ 和 CBD Clinic™，定位以健康、自我护理和功能性用途为中心。核心产品类别包括液体大麻提取物酊剂、软糖、胶囊、外用乳霜和乳液、宠物产品，以及最近的功能性蘑菇软糖。这种广泛但仍有重点的产品范围使公司能够满足多种消费者需求，例如睡眠、镇静、日常健康、恢复和局部缓解。([sec.gov](https://www.sec.gov/Archives/edgar/data/1750155/000175015526000029/cweb-20251231.htm?utm_source=openai)) 在运营方面，Charlotte’s Web 依赖于一个整合模型，涵盖北美农场种植的大麻投入、提取、制造、质量控制、研发和分销。一个关键资产是其位于路易斯维尔的符合 cGMP 标准的生产设施，公司在此生产酊剂并管理分销和质量系统。其产品通过选定的分销商、医疗保健从业者、公司自己的网站和第三方电子商务渠道销售。这种垂直整合在一个产品一致性、信任和合规性可能成为决定性竞争因素的类别中至关重要。([sec.gov](https://www.sec.gov/Archives/edgar/data/1750155/000175015526000029/cweb-20251231.htm?utm_source=openai)) 从竞争角度来看，Charlotte’s Web 将自己描述为美国大麻提取物健康产品市场的领导者。其竞争优势在于品牌知名度、专有大麻遗传学、多元化的 SKU 设置以及在一个仍在发展的消费健康利基市场中的长期运营历史。同时，该业务仍然面临定价压力、消费者需求波动以及围绕大麻衍生产品的监管不确定性。对于股权投资者而言，投资案例因此是品牌资产和执行风险之间的平衡。([sec.gov](https://www.sec.gov/Archives/edgar/data/1750155/000175015526000029/cweb-20251231.htm?utm_source=openai)) 最近的一个重大进展发生在 2026 年 3 月 30 日至 31 日，当时公司宣布与 BAT 达成一项交易，涉及将 75.3 million 加元的可转换债券转换为普通股，并同时进行 10 million 美元的股权投资。该交易具有战略重要性，因为它可能实质性地重塑公司的所有权结构和资本基础。公司还在 2026 年 3 月下旬公布了 2025 年年度业绩，继续强调其在 CBD 大麻提取物健康产品领域的领导地位。对于法国、比利时和瑞士的投资者而言，Charlotte’s Web 最好的特点是作为一家投机性的美国消费健康小盘股，具有显著的稀释、融资和执行考量，但拥有公认的品牌和在美国健康市场中的明确利基。([sec.gov](https://www.sec.gov/Archives/edgar/data/0001750155/000175015526000029/cweb-20251231.htm?utm_source=openai))
